Pharmacotherapies for COPD

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Volumn 7, Issue 1, 2013, Pages 17-34

  Ejiofor, Stan ^a   Turner, Alice M ^b,c  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Disease management; Pharmacotherapies

Indexed keywords

ACETYLCYSTEINE; ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CARBOCISTEINE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; LONG ACTING BETA AGONIST; LONG ACTING MUSCARINIC ANTAGONIST; MUCOLYTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; OPIATE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; SHORT ACTING BETA AGONIST; SHORT ACTING MUSCARINIC ANTAGONIST; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; DYSPNEA; GASTROINTESTINAL SYMPTOM; HUMAN; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NAUSEA; NONHUMAN; OXYGEN THERAPY; PNEUMONIA; RESPIRATION DEPRESSION; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING CESSATION; TACHYCARDIA; THRUSH; TREMOR; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84876958212     PISSN: 11795484     EISSN: None     Source Type: Journal    
DOI: 10.4137/CCRPM.S7211     Document Type: Review

References (136)

1. Global Initiative for Obstructive Lung Disease. http://www.goldcopd.com. Accessed Sep 21, 2012.
2. Anthonisen NR, Manfreda J, Warren CP, Hershfeld ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-1204.
3. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1): 1418-1422.
4. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852.
5. National Institute for Health and Clinical Excellence. Chronic Obstructive Pulmonary Disease. http://www.nice.org.uk/CG1012010. Jun 2010.
6. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. J Assoc Physicians India. 2009;33(5):1165-1185.
7. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962-969.
8. Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinfation and breathlessness in hyperinfated patients with COPD. COPD. 2011;8(5):340-345.
9. Cooper CB. Airfow obstruction and exercise. Resp Med. 2009;103(3): 325-334.
10. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic efficacy: measurement and clinical signifcance. Am J Respir Crit Care Med. 2002;165(10):1353-1358.
11. Fazio F, Lafortuna C. Effect of inhaled salbutamol on mucociliary clearance in patients with chronic bronchitis. Chest. 1981;80(Suppl 6):827-830.
12. Maris NA, van der Sluijs KF, Florquin S, et al. Salmeterol, a beta2-receptor agonist, attenuates lipopolysaccharide-induced lung infammation in mice. Am J Physiol Lung Cell Mol Physiol. 2004;286(6):L1122-L1128.
13. Tomlinson PR, Wilson JW, Stewart AG. Inhibition by salbutamol of the proliferation of human airway smooth muscle cells grown in culture. Br J Pharmacol. 1994;111(2):641-647.
14. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;3:CD006101.
15. van Noord JA, Smeets JJ, Maesen FP. A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoc-onstriction. Res Med. 1998;92(12):1346-1351.
16. Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol. 1986;22(5):587-593.
17. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD009157.
18. Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther. 2012;37(2):204-11.
19. Ball DI, Brittain RT, Coleman RA, et al. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol. 1991;104(3):665-71.
20. Benhamou D, Cuvelier A, Muir JF, et al. Rapid onset of bronchodila-tion in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Resp Med. 2001;95(10): 817-21.
21. Celik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration. 1999;66(5):434-439.
22. Green SA, Spasoff AP, Coleman RA, Johnson M, Liggett SB. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem. 1996;271(39):24029-24035.
23. Manchee GR, Barrow A, Kulkarni S, et al. Disposition of salmeterol xin-afoate in laboratory animals and humans. Drug Metab Dispos. 1993;21(6): 1022-1028.
24. Rosenborg J, Larsson P, Tegner K, Hallstrom G. Mass balance and metabolism of [(3)H]Formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation. Drug Metab Dispos. 1999;27(10): 1104-1116.
25. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997;10(4):815-821.
26. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115(4):957-965.
27. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(5):1087-1092.
28. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and futicasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-456.
29. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and futicasone propi-onate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
30. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(5):778-784.
31. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerabil-ity, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002;121(4):1058-1069.
32. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912-919.
33. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/ formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74-81.
34. Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. Apr 2013;26(2):256-264.
35. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-o ne (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther. 2006;317(2):762-770.
36. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155-162.
37. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473-479.
38. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797-803.
39. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37(2):273-279.
40. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respiratory Medicine. 2011;105(5):719-26.
41. Salpeter SR. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs and Aging. 2004;21(6):405-414.
42. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008;133(5):1079-1087.
43. Lipson DA. Tiotropium bromide. Int J Chron Obstruct Pulmon Dis. 2006; 1(2):107-114.
44. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000;55(4):289-294.
45. Kerwin E, Hebert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012;40(5):1106-1114.
46. Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 mug twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012;141(3):745-752.
47. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotro-pium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399-404.
48. Briggs DD Jr, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salme-terol in patients with COPD. Pulmonary Pharmacology and Therapeutics. 2005;18(6):397-404.
49. Tashkin DP, Celli B, Senn S, et al. A 4 year trial of tiotropium in COPD. N Engl J Med. 2008;359:1543-1554.
50. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12): 1093-1103.
51. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011;12:156.
52. Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011;12: 55.
53. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012;40(4):830-836.
54. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9(2):90-101.
55. Haddad EB, Mak JC, Barnes PJ. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Molecul Pharmacol. 1994;45(5):899-907.
56. Turck D, Weber W, Sigmund R, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol. 2004;44(2):163-172.
57. Sykes DA, Dowling MR, Leighton-Davies J, et al. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012;343(2):520-528.
58. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009;330(2): 660-668.
59. Sechaud R, Renard D, Zhang-Auberson L, Motte Sde L, Drollmann A, Kaiser G. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD). Int J Clin Pharmacol Ther. 2012;50(2):118-128.
60. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profle. J Pharmacol Exp Ther. 2009; 331(2):740-751.
61. Schmid K, Pascual S, Gil EG, Ortiz S, Jansat JM. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial. Clin Ther. 2010;32(10):1798-1812.
62. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12): 1439-1450.
63. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4 year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:948-955.
64. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotro-pium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215.
65. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD009285.
66. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68(1):48-56.
67. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I. Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010;7(1):187-195.
68. Brand P, Meyer T, Weuthen T, et al. Lung deposition of radiolabeled tiotro-pium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2007;47(10):1335-1341.
69. Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4): 763-770.
70. Beasley R, Singh S, Loke YK, Enright P, Furberg CD. Call for worldwide withdrawal of tiotropium Respimat mist inhaler. BMJ. 2012;345: e7390.
71. British Thoracic Society. British Guideline on the Management of Asthma. http://thorax.bmj.com/content/63/Suppl_4/iv1.full.pdf. 2008.
72. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183-192.
73. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD002991.
74. Ito K, Yamamura S, Essilfe-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 2006;203(1):7-13.
75. Barnes PJ. Development of New Drugs for COPD. Curr Med Chem. Sep 3, 2012. [Epub ahead of print.]
76. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of futicasone propi-onate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297-1303.
77. Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: phar-macokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(4):356-363.
78. Dalby C, Polanowski T, Larsson T, Borgstrom L, Edsbacker S, Harrison TW. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/futicasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res. 2009;10:104.
79. Holme J, Tomlinson JW, Stockley RA, Stewart PM, Barlow N, Sullivan AL. Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J. 2008;32(4):1047-1052.
80. van Noord JA, Buhl R, Laforce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010;65(12):1086-1091.
81. Johnson M. Interactions between corticosteroids and beta2-agonists in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(3):200-206.
82. Mattila MJ, Salonen RO. Modifcation by betamethasone of the effects of bronchodilator drugs on cholinergic bronchoconstriction in rats. Br J Pharmacol. 1984;83(3):607-614.
83. Hui KK, Conolly ME, Tashkin DP. Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids. Clin Pharmacol Ther. 1982; 32(5):566-571.
84. Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol. 1995; 268(1 Pt 1):L41-L46.
85. Jones PW, Anderson JA, Calverley PM, et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res. 2011;12:71.
86. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4): 332-338.
87. Jenkins CR, Jones PW, Celli B, et al. Efficacy of salmeterol and futicasone propionate by GOLD stage of COPD: analysis from the randomised, pla-ceo controlled TORCH study. Respir Res. 2009;10:59.
88. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/futicasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19-26.
89. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.
90. Halpin DM, Gray J, Edwards SJ, Morais J, Singh D. Budesonide/ formoterol vs. salmeterol/futicasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract. 2011;65(7):764-774.
91. Giembycz MA, Field SK. Rofumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther. 2010;4:147-158.
92. Bethke TD, Hartmann M, Hunnemeyer A, Lahu G, Gleiter CH. Influence of renal impairment on the pharmacokinetics of oral rofumilast: an open-label, parallel-group, single-center study. Int J Clin Pharmacol Ther. 2011;49(8):491-499.
93. Rennard SI, Schachter N, Strek M, Rickard K, Amit O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest. 2006;129(1):56-66.
94. Rovei V, Chanoine F, Strolin Benedetti M. Pharmacokinetics of theophyl-line: a dose-range study. Br J Clin Pharmacol. 1982;14(6):769-778.
95. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor rofumilast-the importance of defning different subsets of patients with COPD. Respir Res. 2011;12:18.
96. Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;4: CD003902.
97. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophyl-line combination therapy in the treatment of COPD. Chest. 2001;119(6): 1661-1670.
98. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Rofumilast-an oral anti-infammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366(9485): 563-571.
99. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with rofumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2): 154-161.
100. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Rofumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685-694.
101. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Rofumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374(9691):695-703.
102. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J. 2004;23(4):629-636.
103. Hooper C, Calvert J. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(4):659-669.
104. Dekhuijzen PN, van Beurden WJ. The role for N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(2): 99-106.
105. Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;8:CD001287.
106. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552-1560.
107. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93(3):391-398.
108. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1(8222):681-686.
109. Stoller JK, Panos RJ, Krachman S, Doherty DE, Make B. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. Chest. 2010;138(1):179-187.
110. O'Neill B, Mahon JM, Bradley J. Short-burst oxygen therapy in chronic obstructive pulmonary disease. Respir Med. Jul 2006;100(7):1129-38.
111. Fletcher C, Peto R. The natural history of chronic airfow obstruction. BMJ. 1977;1(6077):1645-1648.
112. Fagerstrom K, Balfour DJ. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs. Feb 2006;15(2):107-116.
113. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;1:CD000031.
114. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103.
115. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:CD000146.
116. Ahmed AI, Ali AN, Kramers C, Harmark LV, Burger DM, Verhoeven WM. Neuropsychiatric adverse events of varenicline: a systematic review of published reports. J Clin Psychopharmacol. 2013;33(1):55-62.
117. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizo-affective disorder. J Clin Psychiatry. 2012;73(5):654-660.
118. Rocker G, Horton R, Currow D, Goodridge D, Young J, Booth S. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax. 2009;64(10):910-915.
119. Weil JV, McCullough RE, Kline JS, Sodal IE. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N Engl J Med. 1975;292(21):1103-1106.
120. Santiago TV, Johnson J, Riley DJ, Edelman NH. Effects of morphine on ventilatory response to exercise. J Appl Physiol. 1979;47(1):112-118.
121. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939-944.
122. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523-528.
123. Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. Sep 27, 2012. [Epub ahead of print.]
124. Vonbank K, Ziesche R, Higenbottam TW, et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax. 2003;58(4):289-293.
125. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J. 2008;32(3):619-628.
126. Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2009;3(1):15-21.
127. Rao RS, Singh S, Sharma BB, Agarwal V V, Singh V. Sildenafl improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Indian J Chest Dis Allied Sci. 2011;53(2):81-85.
128. Lederer DJ, Bartels MN, Schluger NW, et al. Sildenafl for chronic obstructive pulmonary disease: a randomized crossover trial. COPD. 2012; 9(3):268-275.
129. Janssens W, Bouillon R, Claes B, et al. Vitamin D defciency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax. 2010;65(3):215-220.
130. Wood AM, Bassford C, Webster D, et al. Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax. 2011;66(3):205-210.
131. Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2012;156(2):105-114.
132. Creutzberg EC, Wouters EF, Mostert R, Weling-Scheepers CA, Schols AM. Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition. 2003;19(2):120-127.
133. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64(8):728-735.
134. Hardin M, Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127.
135. Soler-Cataluna JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Archivos de Bronconeumologia. 2012;48(9):331-337.
136. Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2012;7:283-289.